Effect of saralasin in hypertensive patients on chronic hemodialysis

M. D. Lifschitz, M. A. Kirschenbaum, S. G. Rosenblatt, R. Gibney

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Hypertension in patients on chronic hemodialysis is thought to be largely of two types - volume dependent or renin dependent. If renin-dependent hypertension is mediated by angiotensin II, then angiotensin II antagonism should lower blood pressure. To test this hypothesis, the angiotensin II antagonist saralasin was given to 15 hypertensive patients on chronic hemodialysis. Patients were separated into two groups by their blood pressure response. In responders blood pressure was 191/112 mm Hg and fell to 147/85 during saralasin administration (P<0.01). In contrast, nonresponders had blood pressures of 190/111 mm Hg before and 188/110 during saralasin administration. Five responders subsequently had nephrectomies with normalization of their blood pressure. Plasma renin activity averaged 70 ng/ml x 3h of angiotensin I in responders and increased to 110 after saralasin (P<0.05), while nonresponders had values of 21 before and after saralasin. These results offer strong support for the hypothesis that renin-dependent hypertension is an important mechanism in certain patients on chronic hemodialysis and that such patients will respond to angiotensin II antagonism.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalAnnals of internal medicine
Issue number1
StatePublished - 1978

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Effect of saralasin in hypertensive patients on chronic hemodialysis'. Together they form a unique fingerprint.

Cite this